Mirikizumab

A biologic that blocks the inflammatory protein IL-23.

Also called: omvoh, mirikizamab

Related words interleukin inhibitor biologic

Topics Biologics and newer medicines

Questions people ask

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

Which biologics and targeted medicines are approved for Crohn's on the NHS?

NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.

Sources

Where to read more

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Systematic review May 2025 Patients and professionals

Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.

Topics Biologics and newer medicines

Jargon explained IL-12/23 induction certainty of evidence

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

NICE Guideline Aug 2025 For professionals

NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.

Topics Biologics and newer medicines Medicines

Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment

Guselkumab

Crohn's & Colitis UK Guide Dec 2025 For patients

A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin inhibitor

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Risankizumab

Crohn's & Colitis UK Guide Jul 2023 For patients

A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin biologic

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Search everything for "mirikizumab"